Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial

Condition(s) studied

Investigational drug(s) / intervention(s)

Cadonilimab: 10mg/kg intravenous (IV) every 3 weeks ;

Oxaliplatin: 130mg/m², iv drip for 2h, d1, q3w;

Capecitabine: 1000mg/m² po, Bid, d1-14, q3w ;

Study summary

For locally advanced esophagogastric junction and gastric cancer, neoadjuvant chemotherapy can downstage T and N stage,treated distant micrometastases early , and finally improve the long-term survival. Combination of perioperative PD-1 antibody and chemotherapy for locally advanced esophagogastric junction and gastric cancer could be a novel therapy to increase response rate and reduce recurrence rate.Cadonilimab, a tetravalent bispecific antibody targeting PD-1 and CTLA-4, is designed to retain the efficacy benefit of combination of PD-1 and CTLA-4 and improve on the safety profile of the combination therapy. The aim of this study is to evaluate the efficacy and safety of cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer.

Eligibility

Primary outcome measure(s)

• Pathologic complete remission rate (pCR) — up to 1 years
  Pathological complete response (pCR) rate is defined as the proportion of participants whose tumor in the stomach and lymph node completely disappeared, as determined by a pathologist.

Trial sites (1)

More Nanfang Hospital, Southern Medical University trials in China

Other trials for the same condition